EvidenceHunt Raises €1.2M to Expand AI-Powered Medical Research Platform
EvidenceHunt launched its platform 18 months ago following two years of research and scientific validation.
Company Name: EvidenceHunt
Location: Amsterdam, Netherlands
Industry: Health Tech
Funding Details:
- Amount: €1.2M
- Investors:
- Lead: Keen Venture Partners, Dff.ventures, Slimmer AI
- Participants: Angel investors, including:
- Jeroen Tas (former Chief Strategy and Innovation Officer at Philips)
- Dinko Valerio (former CEO & Founder of Crucell)
- James Shannon (former Head of Global Drug Development at Novartis)
Purpose of Investment:
- Expand platform capabilities for processing medical information
- Enhance AI-driven evidence analysis and summarization tools
- Scale user adoption among healthcare professionals, researchers, and organizations
Leadership:
- CEO: Philippe Habets
Product:
EvidenceHunt provides an AI-powered medical research platform that allows healthcare professionals and researchers to:
- Instantly analyze and extract insights from medical literature
- Ask complex questions and receive summarized, cited responses
- Verify AI-generated answers with trackable details for accuracy
About the Company:
EvidenceHunt launched its platform 18 months ago following two years of research and scientific validation. It has since grown to a global user base of 25,000 active users across 90+ countries, including professionals in:
- Pharmaceutical & medical device companies
- Healthcare providers
- Academic institutions
With this funding, EvidenceHunt aims to further its mission of accelerating medical research and evidence-based decision-making through AI.
